Fungal Infection News and Research

RSS

Safeguard Scientifics reports financial results for the third quarter of 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.

4 Nov 2009

Diabetes may damage nerves in the skin leading to dry skin, say experts

As American Diabetes Month approaches, leading experts like Dr. Jacqueline Sutera, DPM, stress the importance of foot care, especially for those with diabetes. People with diabetes are at a greater risk of developing dry skin due to nerve damage.

30 Oct 2009

Genetic mutations may put individuals at increased risk for fungal infections

New research has identified two genetic mutations that may put individuals at increased risk for fungal infections. The research focused on patients with severe fungal infections (primarily of the genus Candida), but the findings may also have implications for patients who have more common mild infections.

29 Oct 2009

Scientists identify genetic mutations that may put individuals at increased risk of fungal infections

Two genetic mutations that may put individuals at increased risk of fungal infections have been identified by scientists from UCL and Radboud University, increasing understanding about the genetic basis of these infections and potentially aiding the development of new treatments.

29 Oct 2009

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced it led a $17.4 million Series B financing round for Quinnova Pharmaceuticals, Inc., with participation from existing investors Thomas, McNerney & Partners and H.I.G. BioVentures.

28 Oct 2009

NCMLS organises immunology congress at Nijmegen

How do cells in our immune system recognise dangerous invaders and hazardous cells, such as cancer cells? Answers to this and similar questions are evolving rapidly. A large contributor worldwide to the field of immunology is the NCMLS, Nijmegen Centre for Molecular Life Sciences of the Radboud University Nijmegen Medical Centre. The NCMLS is organising an important scientific congress on this very topic, for which the absolute world top immunology experts are coming to Nijmegen.

27 Oct 2009

Keraderm raises $2.5 million from institutional investor

Keraderm Corp. announced the closing today of a $2.5 million dollar Series A investment by NewVa Capital Partners, LP. Currently starting clinical trials, the company's platform harnesses phototherapy technology to treat nail and skin infections. NewVa Capital Partners is a private equity and venture capital fund managed by Third Security, LLC and provides early stage investments in companies located or considering location in the NewVa region of southwest Virginia. This is Keraderm's first institutional investment round.

24 Oct 2009

Continuing education virtual lecture to help prevent fungal infections in HSCT recipients

Systemic fungal infections are a serious complication of hematopoietic stem cell transplantation (HSCT) and are associated with significant mortality in HSCT recipients. It is critical for healthcare professionals to be aware of the risk factors for fungal infections in HSCT patients and apply optimal strategies for prevention and treatment in this population.

9 Oct 2009

New findings on genetic disorder may lead to better treatment of inflammatory bowel disease

New findings related to an uncommon genetic disorder may impact the diagnosis and treatment of inflammatory bowel disease (IBD), the most common chronic gastrointestinal illness in children and teens.

9 Oct 2009

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced positive results from its Phase 2 clinical study evaluating luliconazole, one of the most potent and broad spectrum topical antifungal agents, in patients with tinea pedis (athlete's foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

6 Oct 2009

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

BioDelivery Sciences International, Inc. has received a $1.3 million grant from the Walter Reed Army Institute of Research for Bioral Amphotericin B, an oral formulation of the fungicidal treatment amphotericin B in BDSI’s patented Bioral drug delivery technology, to further study the formulation in the treatment of Cutaneous Leishmaniasis.

6 Oct 2009

Combined immunodeficiency results in severe health problems

Researchers at the National Institutes of Health have identified a genetic mutation that accounts for a perplexing condition found in people with an inherited immunodeficiency. The disorder, called combined immunodeficiency, is characterized by a constellation of severe health problems, including persistent bacterial and viral skin infections, severe eczema, acute allergies and asthma, and cancer.

28 Sep 2009

Researchers find fungi effective for controlling malaria mosquitoes

In areas where malaria mosquitoes have become resistant to chemical pesticides, mosquito-killing fungi can be an effective tool. Fungal spores can effectively infect and kill malaria mosquitoes, even those that are resistant to pesticides.

25 Sep 2009

Nomir publishes efficacy of the Noveondual-wavelength device against infectious disease pathogens

Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today the publication of a scientific paper in the journal Photochemistry and Photobiology that details in vitro and human data demonstrating the unique and patented mechanism-of-action for its Noveon® dual-wavelength device, as well as positive efficacy and safety data.

16 Sep 2009

Phase III results of Lauriad presented at the 49th Annual ICAAC

BioAlliance Pharma has attended the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco to present results on miconazole Lauriad and anti-integrase inhibitor.

15 Sep 2009

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

15 Sep 2009

Pergamum to develop Karolinska dermatology and wound healing companies

Pergamum AB has announced its formation; Pergamum will commercialize the Karolinska Development dermatology and wound healing interests, and create a broad-based therapeutic company in its focus areas.

11 Sep 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

Karolinska Development announces formation of Pergamum AB business unit

Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.

10 Sep 2009

Microbe's multilayer defence mechanisms could treat fungal infections

Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.

8 Sep 2009